Eton Pharmaceuticals, Inc.

NasdaqGM:ETON 주식 보고서

시가총액: US$83.8m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Eton Pharmaceuticals 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Sean Brynjelsen

최고 경영자

US$1.7m

총 보상

CEO 급여 비율33.9%
CEO 임기7yrs
CEO 소유권4.2%
경영진 평균 재임 기간2.4yrs
이사회 평균 재임 기간6.8yrs

최근 관리 업데이트

Recent updates

Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%

Jan 09
Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%

The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot

Dec 13
The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot

Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point

Nov 16
Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point

Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money

Sep 30
Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money

Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%

Jul 25
Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Jun 29
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?

Dec 22
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?

Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous

Sep 13

Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story

Aug 14

Eton Pharma jumps 20% on FDA approval of seizure therapy

Jul 18

Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher

Apr 15
Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher

Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely

Oct 14
Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely

Another Look At Eton Pharmaceuticals

Sep 03

What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates

Aug 18
What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates

Eton Pharma wins FDA approval for Rezipres

Jun 15

FDA declines to approve Eton Pharmaceuticals' methanol poisoning treatment

May 28

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner

May 15
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Apr 05
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?

Mar 01
Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?

Eton Pharma buys Canadian rights for Alkindi Sprinkle

Jan 14

Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit

Jan 07
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit

FDA accepts Eton application for Topiramate for partial seizures

Dec 17

Eton Pharmaceuticals announces availability of ALKINDI SPRINKLE in U.S.

Nov 24

CEO 보상 분석

Sean Brynjelsen 의 보수는 Eton Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

US$913k

Dec 31 2023US$2mUS$592k

-US$936k

Sep 30 2023n/an/a

US$2m

Jun 30 2023n/an/a

-US$234k

Mar 31 2023n/an/a

-US$6m

Dec 31 2022US$2mUS$570k

-US$9m

Sep 30 2022n/an/a

-US$9m

Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$12m

Dec 31 2021US$2mUS$542k

-US$2m

Sep 30 2021n/an/a

-US$11m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$14m

Dec 31 2020US$2mUS$476k

-US$28m

Sep 30 2020n/an/a

-US$23m

Jun 30 2020n/an/a

-US$21m

Mar 31 2020n/an/a

-US$20m

Dec 31 2019US$2mUS$410k

-US$18m

Sep 30 2019n/an/a

-US$42m

Jun 30 2019n/an/a

-US$40m

Mar 31 2019n/an/a

-US$41m

Dec 31 2018US$493kUS$332k

-US$37m

Sep 30 2018n/an/a

-US$18m

Dec 31 2017US$654kUS$172k

-US$13m

보상 대 시장: Sean 의 총 보상 ($USD 1.75M )은 US 시장( $USD 683.56K ).

보상과 수익: Sean 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Sean Brynjelsen (52 yo)

7yrs

테뉴어

US$1,747,045

보상

Mr. Sean E. Brynjelsen has been the Chief Executive Officer at Eton Pharmaceuticals, Inc. since June 23, 2017 and serves as President and Director since June 2017. Mr. Brynjelsen served as Executive Vice P...

리더십 팀

이름위치테뉴어보상소유권
Sean Brynjelsen
President7yrsUS$1.75m4.18%
$ 3.5m
James Gruber
CFO, Treasurer & Secretary2.2yrsUS$785.14k0.049%
$ 41.1k
David Krempa
Chief Business Officer1.3yrsUS$719.08k0.081%
$ 67.8k
Ingrid Hoos
Senior Vice President of Regulatory Affairs3.8yrs데이터 없음데이터 없음
Kevin Guthrie
Executive VP of Commercial Operations2.4yrs데이터 없음데이터 없음

2.4yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: ETON 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Sean Brynjelsen
President7yrsUS$1.75m4.18%
$ 3.5m
Paul Maier
Independent Director6.8yrsUS$129.50k0.23%
$ 194.8k
Charles Casamento
Independent Director7yrsUS$126.90k0.27%
$ 223.0k
Norbert Riedel
Independent Chairman6.8yrsUS$155.50k0.23%
$ 194.8k
Jennifer Adams
Independent Director3.3yrsUS$119.10k데이터 없음

6.8yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: ETON 의 이사회는 경험(평균 재직 기간 6.8 년)으로 간주됩니다.